Skip to content
CancerIndex

Publication

A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.

Authors not recorded

Science2019PMID 31395785PMC7327437stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (6)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 6

Curated evidence

Evidence citing this paper (7)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
31395785
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–7 of 7 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
TP53 M237I1
(functional)—UNRESOLVEDFunctionalDDoes Not Support Neomorphic4accepted
EID7528

The M237I mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. M237I/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption o… (full text at CIViC)

PMID 31395785 · Boettcher et al., 2019 · Open in CIViC

civic
TP53 R175H1
(functional)—UNRESOLVEDFunctionalDDoes Not Support Neomorphic4submitted
EID7526

The R175H mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. R175H/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption o… (full text at CIViC)

PMID 31395785 · Boettcher et al., 2019 · Open in CIViC

civic
TP53 R248Q2
(functional)—UNRESOLVEDFunctionalDSupports Dominant Negative4accepted
EID7525

CRISPR-Cas9 editing was used to create five isogenic MOLM13-TP53 AML cell lines with combinations of wild-type, mutant, and null TP53 alleles at the endogenous locus: p53+/+, p53+/-, p53-/-, R248Q/+, … (full text at CIViC)

PMID 31395785 · Boettcher et al., 2019 · Open in CIViC

civic
〃—UNRESOLVEDFunctionalDDoes Not Support Neomorphic4accepted
EID7529

The R248Q mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. R248Q/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption o… (full text at CIViC)

PMID 31395785 · Boettcher et al., 2019 · Open in CIViC

civic
TP53 R273H1
(functional)—UNRESOLVEDFunctionalDDoes Not Support Neomorphic4accepted
EID7530

The R273H mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. R273H/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption o… (full text at CIViC)

PMID 31395785 · Boettcher et al., 2019 · Open in CIViC

civic
TP53 R282W1
(functional)—UNRESOLVEDFunctionalDDoes Not Support Neomorphic3accepted
EID7531

The R282W mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. R282W/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption o… (full text at CIViC)

PMID 31395785 · Boettcher et al., 2019 · Open in CIViC

civic
TP53 Y220C1
(functional)—UNRESOLVEDFunctionalDDoes Not Support Neomorphic4accepted
EID7527

The Y220C mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. Y220C/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption o… (full text at CIViC)

PMID 31395785 · Boettcher et al., 2019 · Open in CIViC

civic